Moderna's flu/COVID combination vaccine hit by deprioritization, FDA delay Moderna is deprioritizing< | Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut about $1.5 billion from its operating expenses. The biotech disclosed the changes alongside news of a delay to the expected approval of the vaccine in older adults. Nick Paul Taylor Fierce Biotech

...

FDA chief says they're looking at whether to approve COVID shots for next winter FDA Commissioner Dr. Marty Makary said there is a "void of data" on the COVID booster shots. CBS News

...

His answer marks a change from during the Biden administration, when FDA officials backed plans to routinely update the COVID-19 vaccines each year.

...

Women's Health Initiative gets reprieve from HHS cuts The WHI is the largest and longest study of women's health funded by the National Institutes of Health. Tina Reed Axios

The Trump administration said it's reversing course on a plan to end funding for a decades-long study of women's health after outcry from the research community.

 The Women's Health Initiative was threatened by funding cuts to clinical studies aimed at reducing cancer rates or studying hormone therapy in menopause. Despite the reprieve, researchers remain fearful about its future.

...